Burling Wealth Partners LLC Buys New Holdings in Stryker Co. (NYSE:SYK)

Burling Wealth Partners LLC purchased a new stake in Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 5,368 shares of the medical technology company's stock, valued at approximately $1,933,000.

Other institutional investors also recently added to or reduced their stakes in the company. J. W. Coons Advisors LLC boosted its position in shares of Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC raised its holdings in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after purchasing an additional 27 shares during the last quarter. Opal Wealth Advisors LLC lifted its holdings in shares of Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after buying an additional 28 shares during the period. Lindbrook Capital LLC grew its holdings in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after acquiring an additional 28 shares during the period. Finally, Alhambra Investment Management LLC raised its position in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Citigroup restated a "buy" rating and issued a $450.00 price objective on shares of Stryker in a research report on Wednesday, February 26th. Truist Financial raised their price target on shares of Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. upped their price objective on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Needham & Company LLC restated a "buy" rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Finally, BTIG Research set a $403.00 price target on Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $423.53.

Stryker Trading Up 0.8 %

Shares of Stryker stock traded up $2.76 during trading hours on Tuesday, hitting $369.25. The company's stock had a trading volume of 412,353 shares, compared to its average volume of 1,352,798. The firm has a fifty day moving average of $367.37 and a 200-day moving average of $373.51. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The stock has a market cap of $140.94 billion, a price-to-earnings ratio of 47.55, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company posted $3.46 EPS. Research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. Stryker's dividend payout ratio is currently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.